NCT07175480View on ClinicalTrials.gov

PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 24, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2030

Conditions
Renal Cell Carcinoma (RCC)Metastatic Renal Cell Carcinoma (mRCC)
Interventions
DRUG

Intermittent PD-1/PD-L1 ICI + VEGFR-TKI

Any PD-1/PD-L1 inhibitor or VEGFR-TKI that is commercially marketed, regulatory-approved and reimbursed under public health plans.Dose as recommended by the manufacturer.

Trial Locations (1)

Unknown

RECRUITING

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, Nanjing

All Listed Sponsors
lead

Jinling Hospital, China

OTHER